Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
CRXT was delisted on the 30th of August, 2022.
12 hedge funds and large institutions have $10.5M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
13% less capital invested
Capital invested by funds: $12.1M → $10.5M (-$1.59M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$8.38M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$723K |
| 3 |
PIA
Powell Investment Advisors
Miami,
Florida
|
+$91.2K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$90.3K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$78.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
-$240K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$132K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$120K |
| 4 |
VF
Virtu Financial
New York
|
-$94K |
| 5 |
CAC
Cowen and Company
New York
|
-$53K |
CRXT Hedge Fund Activity: Q4 2021 in Review
12 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q4 2021, worth a combined $10.5M — down 13% from $12.1M a quarter earlier.
Fund positioning in CRXT was balanced in Q4 2021: 7 funds opened new positions, 7 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $8.38M. The largest seller was Telemetry Investments, exiting entirely with an estimated $240K sold.
- 12 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $10.5M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q4 2021, down 13% quarter-over-quarter.
- 7 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q4 2021 and 7 closed out, a net change of 0 holders.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q4 2021 was Armistice Capital, an estimated $8.38M added.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q4 2021 was Telemetry Investments, an estimated $240K sold.
Based on aggregated 13F filings for Q4 2021.